Latest Regulatory Progress News

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Audalia Resources is set to raise $450,000 through a share placement aimed at funding critical mining design and permit work for its Medcalf Project, supporting its path toward development.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies, with Telix receiving a $40 million upfront payment and potential milestones exceeding $2 billion.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.

Viking Mines Limited has reported successful results from an expanded ground gravity survey at its Linka Tungsten Project in Nevada, identifying numerous new high gravity anomalies that correlate with known mineralisation and concealed targets beneath volcanic cover. These findings support the company’s plan to commence drilling in the June quarter.

TMK Energy Limited (ASX: TMK) reported a 48% increase in average daily gas production at its Gurvantes XXXV Coal Seam Gas Project in March 2026, achieving a new peak daily rate before temporarily curtailing output for operational safety. The company also secured a Memorandum of Understanding with Mongolia’s regulator to facilitate power generation and progress towards an exploitation license.

Insignia Financial has received Foreign Investment Review Board approval for its proposed acquisition by Daintree BidCo, clearing a key regulatory hurdle. The scheme now awaits shareholder and court approvals, with the board recommending shareholder support.

Imricor Medical Systems has submitted its NorthStar Mapping System for FDA pediatric label expansion, aiming to accelerate adoption in over 250 US children’s hospitals and broaden its commercial footprint.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

Capricorn Metals delivered 30,358 ounces of gold in Q3 FY26 at the Karlawinda Gold Project, aligning with its mine plan and progressing the Karlawinda Expansion Project with peak construction activity.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.